Á¶Àç¹Î(Jo Jae-Min) - Jeju National University School of Medicine Jeju National University Hospital Department of Internal Medicine
±èÁ¤È£(Kim Jung-Ho) - Gachon University Gil Medical Center Department of Internal Medicine
±èÁö¿µ(Kim Ji-Young) - Jeju National University School of Medicine Jeju National University Hospital Department of Internal Medicine
Çö⸲(Hyun Chang-Lim) - Jeju National University School of Medicine Jeju National University Hospital Department of Pathology
ÀÌÁö¿µ(Rhee Ji-Young) - Jeju National University School of Medicine Jeju National University Hospital Department of Internal Medicine
±ÇÁ¤¹Ì(Kwon Jung-Mi) - Jeju National University School of Medicine Jeju National University Hospital Department of Internal Medicine
ÇÑ»óÈÆ(Han Sang-Hoon) - Jeju National University School of Medicine Jeju National University Hospital Department of Internal Medicine
±è¿ì°Ç(Kim Woo-Kun) - Jeju National University School of Medicine Jeju National University Hospital Department of Internal Medicine
Abstract
Pazopanib is a potent multitargeted tyrosine kinase inhibitor that has been shown to have good efficacy in patients with renal cell carcinoma. A previous phase II trial demonstrated that short-term pazopanib administration was generally well tolerated and showed antitumor activity in patients with early-stage non-small cell lung cancer. Herein, we report on the case of a 66-year-old man with simultaneous metastatic squamous cell carcinoma of the lung and renal cell carcinoma who was treated with pazopanib. The patient showed an unexpected partial response and experienced a 10-month progression-free survival without significant toxicity. To the best of the authors¡¯ knowledge, this is the first report of pazopanib treatment in a non-small cell lung cancer patient in Korea. The results in this patient suggest that pazopanib may be a valid treatment option for advanced non-small cell lung cancer.
Å°¿öµå
Lung neoplasms, Drug therapy, Tyrosine kinase inhibitor, Pazopanib
KMID :
0939920160480010393
¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸
µîÀçÀú³Î Á¤º¸
À¯È¿¼º°á°ú(Recomendation)
a 10-month progression-free survival without significant toxicity. pazopanib may be a valid treatment option for advanced non-small cell lung cancer.